Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
D Mukerjee(The Royal Free Hospital), Gerry Coghlan(Papworth Hospital NHS Foundation Trust), Bernard Coleiro, C Knight(The Royal Free Hospital), Deepa George(Southampton General Hospital), CP Denton(The Royal Free Hospital), C. M. Black(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joseph Davar(The Royal Free Hospital)
Cited by 769
Related Papers
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503
Identification of rare sequence variation underlying heritable pulmonary arterial hypertension
|Nature Communications|2018|395
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis
|The Lancet Respiratory Medicine|2018|215
Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension
|Circulation|2016|214
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
|The Journal of Heart and Lung Transplantation|2020|207